Kintor
Kintor
Kintor

About Us

We focus on dermatology and oncology with substantial unmet medical needs,especially androgen receptor-related diseases,

including alopecia, acne, prostate cancer, liver cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Picture Name

Small-molecule drugs

Kintor Pharma focuses on dermatology and oncology. Our expanded pipeline now includes AR degraders, AR-PROTAC, mTOR inhibitor, Hedgehog inhibitor, and cMyc inhibitor.

Innovative biologics

Kintor Pharma's first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers. 

Combination therapies

To provide the best treatment for prostate and liver cancers and other diseases, Kintor Pharma is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

Picture Name

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a……

Picture Name
Picture Name

Manufacturing base

 Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing bas……

Picture Name
Picture Name

Business operation

 In anticipation of the commercial launch of our products, Kintor……

Picture Name

News Center

2026-09-07

Successful Completion of Long-Term Human Safety Trial Of KT-939

Suzhou, 7 September, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term human safety trial of KT-939, an in-house developed novel and highly effective tyrosinase inhibitor for inhibiting melanin production, was successfully completed on 4 September 2026. A total of 114 subjects received continuous administration of KT-939 for 52 consecutive weeks, and preliminary data indicate that none of them experienced any adverse skin reactions, in line with the 28 week interim clinical results, fully demonstrating the excellent safety profile of KT-939.
Picture Name

2026-08-24

Research findings of MYC/GSPT1 protein degrader GT19630 have been published in Blood, a top international journal in hematology

Suzhou, 24 August, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that a collaborative research paper with The University of Texas MD Anderson Cancer Center was published on August 17, 2026, in Blood, a premier journal in the field of international hematology. The findings demonstrate that GT19630, a novel MYC/GSPT1 degrader independently developed by Kintor, offers a promising therapeutic strategy for MYC-driven hematological malignancies.
Picture Name

2026-06-01

Kx-826 Phase III Clinical Trial And Combination Therapy Study Data For Aga Presented At The 2026 World Congress For Hair Research (Wchr 2026), And Was Selected As An Outstanding Poster

Suzhou, 1 June, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed and potential first-in-class KX-826 data from two important clinical studies was presented at the 14th World Congress for Hair Research (WCHR 2026) held in Seoul, South Korea from May 28 to 31, 2026.
Picture Name
View more
Picture Name

Work at Kintor

We're developing new products to improve human health,and we're looking for people like you to help shape the future at Kintor Pharmaceuticals.We're building a company based on curiosity, talent, and intellectual capital. We provide employees with opportunities for career development and personal growth.lf you're interested  in joining our team, please send your CV to kintor- HR@kintor. com. cn.

Join Us

Kintor